Kailai Ying test water CRO, Kyuszhou Pharmaceuticals synchronized action CDMO began to change...

Following the announcement 10 days ago of a $7 million investment in Snapdragon Chemistry, an American continuous reaction technology company, Klein invested another $30 million! The deal is for Crown Pharmaceuticals, a 13-year-old clinical CRO company.
note that this is the only two deals in the form of equity investments since the listing.
Has always been a CXO company in the industry with a "technical" tone, with little "capital operation" and no printing, and the two deals in the past two weeks have been described as "groundbreaking" for Klein.
as the first team of domestic chemical CDMO, Kailein such unusual action, especially caused concern.
, but in reality, it's not Klein who's changing, it's the CXO industry as a whole.
Jiuzhou Pharmaceuticals, the second-ranked company in the second tier, and Kailaiying have released plans to raise 1 billion yuan for the construction of the CDMO research and development center, including 280 million yuan for the Novarma Suzhou plant, which was purchased last year for 790 million yuan.
CDMO company action frequency, behind the pusher is exactly what, the current CDMO field is what state? 01 Head CDMO vertical integration opened since the 2015 consistent evaluation proposed that, to the drug market licensing system (MAH), the CXO industry is seen by capital as a new drug development "water seller", towards the development of a golden period, because of the high certainty of the capital market to C XO companies are particularly favored, such as Drug Mingkang has become a 300 billion market value of the company, Pharmaceutical Ming Bio into the 200 billion market value file, Kanglong into a quasi-100 billion market value file, and Tag Pharmaceuticals, Kailei Ying and so on have more than 50 billion market value.
because of this certainty and natural favor, CXO industry competitors emerged, market competition began to intensify.
to maintain their competitive advantage, they must invest heavily to expand vertically into the entire pharmaceutical outsourcing industry chain and build their own moulds.
such as from CRO to CDMO, or from CDMO to CRO, to achieve industry-wide integration.
drug Mingkangde belongs to the former, and Kailaiying belongs to the latter.
2000, when the drug was established, it only did drug discovery and preclinical business, from new drug research and development chemistry, establishment process research and development, API/intermediate production services, toxicology and preparation services continued to improve.
successfully developed vertical integration into the CMO business in 2007 through the acquisition of Chemdepo, a chemical synthesis provider, Abgent, a biologics provider, and two concentrated acquisitions by Chinese clinical research services companies Jiecheng and MedKey, as well as in 2011 and 2014.
today, the chemical CDMO company under the pharmaceutical ming system, the whole pharmaceutical industry, biological CDMO company pharmaceutical ming biological, CRO drug mingkangde and other companies have become the leading enterprises in various sub-sectors.
with the outsourcing price, it is obvious that the integration of the industrial chain of pharmaceutical Mingkang has formed a price advantage.
, which built a CXO empire through acquisitions, provides a model for later companies that want vertical integration.
, Kailaiying, which has been drilling in technology, has also begun to "rise up" towards vertical integration.
August 27th, Calein announced that it intends to subscribe for 18.18 percent of Snapdragon Chemistry for $7 million of its own funds.
founded in 2014, the company is dedicated to the research, development and industrial application of disruptive technology continuity response in the production of innovative pharmaceutical raw materials.
In fact, Kaileiying is the first CDMO company to invest in continuous reaction technology, due to the early investment, Kaileiying through continuous learning, accumulation of experience, has become one of the very few companies in the world can apply continuous reaction technology in the commercial production of medicine and pilot production.
It is understood that the current continuous reaction technology can cover process optimization, API production, intermediate production and finished drug production three links, and these three links are currently the cumulative application of continuous reaction of more than 100 pharmaceutical companies, including Pfizer, AbbVie, GSK, Novart, Lilly and other well-known MNC.
market estimates that the continuous commercial production of small molecule drugs will increase from $280 million in 2020 to $11 million in 2030.
is also Klein's most unique competitive advantage as a chemical CDMO company.
However, for Kailaiying, the real first step may be the acquisition of Guanqin Pharmaceuticals, although the amount is only 30 million yuan, but this is a few of Kailaiying's foreign investment, and is vertical integration of investment.
it is understood that Crown Pharmaceuticals is a CRO company with two major preclinical and clinical service platforms, and the scope of business is summarized as the business area of Tagg Pharmaceuticals and Preclinical CRO.
02 the second echelon CDMO to do deep plus code and small and medium-sized enterprises are limited by the financial strength, can only be deepened in technology, do deep CDMO or CRO, in their own field to attack the city slightly, especially CDMO this needs heavy asset investment industry.
Kyuschu Pharmaceuticals and Pharmaceutical Stone Technology are at this stage.
September 8, Kyuszhou Pharmaceuticals issued a non-public offering plan to raise 1 billion yuan to invest in the CDMO field. according to the
announcement, the funds raised are mainly used for the Ruibo (Suzhou) Pharmaceutical Research and Development Center Project, the Ruibo (Hangzhou) Pharmaceutical Research and Development Center Project, the Zhejiang 4D Pharmaceutical CDMO Preparation Project, the Zhejiang 4D Pharmaceutical 10 billion tablet preparation project (Phase I) and supplementary working capital.
it is learned that Kyuszhou Pharmaceutical Owners Business for patented pharmaceutical raw materials and intermediates, specialty raw materials and intermediates, in recent years, the company has been in the field of code CDMO investment.
For example, 280 million yuan of the fund raised was invested in Ruibo (Suzhou), the company was last year for 790 million yuan to buy the Novarca Suzhou plant, by Jiuzhou Pharmaceuticals as a multinational pharmaceutical companies and domestic head innovation pharmaceutical enterprises CDMO business an important window.
the project, it will form 330 batches/year of API research and development scale.
Suzhou Rebo has now taken orders from Novaral's three major varieties and is in urgent need of expanding production capacity.
the investment project landed, will open Suzhou Ruibo production capacity space to meet the needs of more projects commercial production capacity.
Guosheng Securities believes that the fund-raising plan will further enhance the service level of API, extend the layout of downstream high-end preparation business, to API-preparation research and development and production of one-stop integrated service providers upgrade.
Pharmaceutical Stone Technology also submitted a fund-raising plan of 935 million yuan on July 14 this year, of which about 400 million yuan will be invested in the construction of pharmaceutical preparation production base, the construction of FDA-compliant preparation CDMO production capacity, the company's service phase from intermediates, APIs, extended to preparations, improve the amount of value at the same time, will further bind customers.